Metaplastic Breast Cancer- Publications

9/2017 Metaplastic breast carcinoma: Analysis of 31 cases from a single institute

Purpose: Metaplastic carcinoma of the breast (MBC) accounts for less than 1% of all mammary tumors. This study aimed at revision of the clinico-pathological features, treatment strategy and outcome for MBC patients presented to the Kuwait Cancer Control Center to define the clinical behavior and prognostic factors of these neoplasms in our population.

To read this study in its entirety click here

7/2017  The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas

Purpose: Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic type of breast cancer, predominantly of triple-negative phenotype, and characterized by the presence of malignant cells showing squamous and/or mesenchymal differentiation. We sought to define the repertoire of somatic genetic alterations and the mutational signatures of MBCs.

To read this study in its entirety click here

5/2017 The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database.

Background: Metaplastic breast cancer (MBC) is a rare, aggressive, sarcomatoid breast cancer that was first described in 1973 but only became recognized as a histologically distinct entity in 2000. Given the paucity of data on the epidemiology of MBC, we performed a population-based analysis to delineate sociodemographic and clinicopathological characteristics associated with increased likelihood of MBC diagnosis.

To read this study in its entirety click here.

2/2017 Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution

Background: Metaplastic breast carcinoma (MBC) is a rare and aggressive histologic subtype of breast cancer comprising approximately 0.5% to 5.0% of all invasive breast cancers with a poor prognosis and limited therapeutic options. We investigated MBC at our institution to evaluate outcomes and investigate the molecular profile of our cohort to determine the presence of mutations for which there are targeted therapies.

To read this study in its entirety click here.

12/2016 Metaplastic carcinoma of the breast: A case series and review of the literature

Purpose: Metaplastic breast carcinoma (MBC) is a rare aggressive type of breast cancer, which accounts
for less than 1% of breast tumors. Since its recognition as a distinct pathological entity in 2000, number of
MBC patients has been increasing over years. We aimed to report a series of 7 cases of MBC treated in our
clinics

To read this study in its entirety click here.

6/2016 Management and Outcomes in Metaplastic Breast Cancer.

Background: Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research. Potential novel targeted therapies could provide a hope for better outcomes but limited data are available owing to the rarity of MBC. As knowledge accumulates on the pathogenesis and genetic characteristics of MBC, emphasis should be given to the implementation of more targeted treatments, which will allow more efficient and individualized management of the disease.

To read this study in its entirety click here.

12/2015 Comprehensive Profiling of Metaplastic Breast Carcinoma Reveals Frequent Over-Expression of PD-L1

Background : Metaplastic breast carcinoma (MBC) is a rare subtype of breast carcinoma less responsive to conventional chemotherapy relative to usual breast carcinomas such as ductal and lobular subtype. In molecular terms, MBC usually clusters with triple negative breast cancers (TNBC), but MBCs portray a worse prognosis in comparison with TNBC. Published studies investigating MBCs for specific biomarkers of therapy response are rare and limited by the methodological approaches.

To read more about this poster presentation click here.

12/2015 Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer

Abstract: Metaplastic breast carcinoma (MBC) differs from classic invasive ductal carcinomas regarding incidence, pathogenesis, and prognosis. The purpose of this study was to compare patients with MBC with clinicopathologic and treatment-matched patients with triple-negative breast carcinoma (TNBC) in terms of response to treatment, progression, and survival.

To read this study in its entirety click here.

7/2015 Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

Background: Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase) alterations; thus, therapy with mTor inhibitors may demonstrate activity.

To read this study in its entirety click here.

2/2015 Metaplastic Breast Cancer: Clinical Overview and Molecular Aberrations for Potential Targeted Therapy

Abstract: Metaplastic breast cancer is a rare subtype of invasive mammary carcinoma, with an aggressive behavior and usually poor outcome. Responses to systemic chemotherapy are suboptimal compared to patients with standard invasive ductal carcinoma. Limited data are available in regards to best treatment modalities, including chemotherapy. This review gives an overview of metaplastic breast cancer and its clinical and pathologic characteristics, in addition to treatment strategies, clinical trials, and future directions.

To read this study in its entirety click here.

10/2014 Carcinosarcoma Masquerading as Giant Cystic Hematomasurekha

Abstract: Carcinoarcoma of breast is rare tumor with aggressive behaviour and poor prognosis. Histologically it is biphasic tumor with epithelial and mesenchymal component. Very few cases of carcinosarcoma, its presentation and behaviour have been reported in the literature, and due to its bizarre behaviour it is a diagnostic challenge to pathologist and clinicians. Here we present a rare case of carcinosarcoma breast in a 55-year-old female who initially presented with cystic mass( lump) in right breast which was reported as organised hematoma on FNAC, on frozen divtion it was diagnosed as malignant cystic tumour. This was followed by mastectomy. Histopathology with immune markers, the case was diagnosed as metaplastic carcinoma with biphasic type called carcinosarcoma. The case merits presentation because of its rare presentation as cystic lesion and difficult to diagnose mainly due to sarcomatous elements. An accurate diagnosis of this aggressive tumour is essential in order to optimally tailor adjuvant therapy.

To read this study in its entirety click here.

11/2013  Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies

Abstract: Metaplastic breast cancer (MBC) is a rare subtype of invasive breast cancer that tends to have an aggressive clinical presentation as well as a variety of distinct histologic designations. Few systemic treatment options are available for MBC, as it has consistently shown a suboptimal response to standard chemotherapy regimens. These characteristics result in a worse overall prognosis for patients with MBC compared to those with standard invasive breast cancer. Due to its rarity, data focusing on MBC is limited. This review will discuss the clinical presentation, breast imaging findings, histologic and molecular characteristics of MBC as well as potential future research directions.

To read this study in its entirety click here.

9/2014 Metaplastic Breast Cancer: Pathological Subtypes, Clinical Presentation, Imaging Characteristics, Immunohistochemistry, Treatment and Prognosis.

Abstract: Metaplastic breast cancer is a rare subtype of breast cancer that is histologically heterogeneous, being composed of both sarcomatous and epithelial components. It presents as rapidly growing palpable masses. Incidence of nodal metastasis is low, as compared to intraductal carcinoma, but it has a high metastatic potential and more chances of local recurrence. Many different pathological classifications are available, the most popular being “Wargotz and Norris classification”. Imaging features mimic those of intraductal carcinoma. Immunohistochemically, these tumors show a basal/myoepithelial phenotype with positivity for cytokeratins, AE1/AE3, smooth muscle actin, p63, alpha B-crystallin, etc. These tumors show no or very low positivity for hormone receptors or HER-2 over expression. Therefore, they are often called triple negative carcinomas. They are aggressive tumors with suboptimal response to standard chemotherapy regimens. Overall prognosis of the patients with metaplastic breast cancer is worse than the patients with intraductal breast carcinoma. Further research is needed for formulating targeted therapies for this aggressive tumor.

To read this study in its entirety click here.

2/2006 Biphasic metaplastic sarcomatoid carcinoma of the breast

Background: Breast biphasic metaplastic sarcomatoid carcinoma (MSC) is rare and aggressive. We analyzed 100 patients treated at M. D. Anderson Cancer Center (MDACC) with 213 MSC and 98 carcinosarcoma patients identified through the Surveillance, Epidemiology and End-Results (SEER) database to describe clinical and pathologic characteristics.

To read this study in its entirety click here.